Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab (original) (raw)
Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC)
E. Guedj
NeuroImage: Clinical, 2019
View PDFchevron_right
Impact of Reference/Target Region Selection on Amyloid PET Standard Uptake Value Ratios in the Phase 1b PRIME Study of Aducanumab
Alex Zijdenbos
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018
View PDFchevron_right
Augmenting Amyloid PET Interpretations With Quantitative Information Improves Consistency of Early Amyloid Detection
Jeffrey Burns
Clinical Nuclear Medicine, 2017
View PDFchevron_right
Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study
Zuzana Walker
Neurology, 2009
View PDFchevron_right
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Agneta Nordberg
European Journal of Nuclear Medicine and Molecular Imaging, 2013
View PDFchevron_right
Amyloid and tau PET demonstrate region-specific associations in normal older people
Samuel Lockhart
NeuroImage, 2017
View PDFchevron_right
PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome
Bradley Christian
NeuroImage, 2021
View PDFchevron_right
Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging
Yoshiki Sekijima
European Journal of Nuclear Medicine and Molecular Imaging, 2017
View PDFchevron_right
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine
Flavio Nobili
European Journal of Nuclear Medicine and Molecular Imaging, 2013
View PDFchevron_right
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Lisa Ford
Alzheimer's & Dementia, 2020
View PDFchevron_right
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification
Gregory Klein
The Journal of Nuclear Medicine, 2022
View PDFchevron_right
Clinical Validation of 18F-AZD4694, an Amyloid- -Specific PET Radioligand
Maria Eriksdotter
Journal of Nuclear Medicine, 2012
View PDFchevron_right
The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images
Mellanie Didier
Diagnostics
View PDFchevron_right
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study
Kewei Chen
The Lancet Neurology, 2012
View PDFchevron_right
Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters
Sonia Maria Dozzi Brucki
European Journal of Nuclear Medicine and Molecular Imaging, 2020
View PDFchevron_right
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Mahnaz Shekari
European Journal of Nuclear Medicine and Molecular Imaging
View PDFchevron_right
Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach
Alice Murphy
Alzheimer's Research & Therapy, 2021
View PDFchevron_right
{"__content__"=>"Estimation of amyloid distribution by [F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.", "sup"=>{"__content__"=>"18"}}
Azzam Ismail
Acta neuropathologica, 2018
View PDFchevron_right
Quantitative and statistical analyses of PET imaging studies of amyloid deposition in humans
Simon Davis
2004
View PDFchevron_right
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Katarzyna Adamczuk
NeuroImage: Clinical, 2013
View PDFchevron_right
Definition of a Threshold for the Plasma Aβ42/Aβ40 Ratio Measured by Single-Molecule Array to Predict the Amyloid Status of Individuals without Dementia
Pascal Kienlen-Campard
International Journal of Molecular Sciences, 2024
View PDFchevron_right
Amyloid PET imaging using AZD4694 and unusually brief radiotracer uptake and scanning periods
Kewei Chen
Alzheimer's & Dementia, 2012
View PDFchevron_right
Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies?
Bengt Långström
European Journal of Nuclear Medicine and Molecular Imaging, 2012
View PDFchevron_right
Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association
Peter Herscovitch
Alzheimer's & Dementia, 2013
View PDFchevron_right
(18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging. 10.1007/s00259-015-3228-x
Stephen Keevil
2015
View PDFchevron_right
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
Matthew Senjem
Neurology, 2013
View PDFchevron_right
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B
Scott Ziolko
Journal of Cerebral Blood Flow & Metabolism, 2005
View PDFchevron_right
Prevalence of Amyloid PET Positivity in Dementia Syndromes
Agneta Nordberg
JAMA, 2015
View PDFchevron_right
MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice
Qing X Yang
Journal of Magnetic Resonance Imaging, 2009
View PDFchevron_right
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
John O'Gorman
Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2016
View PDFchevron_right
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Agneta Nordberg
Brain, 2006
View PDFchevron_right